# Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients

> **NCT05334654** · NA · COMPLETED · sponsor: **University Magna Graecia** · enrollment: 58 (actual)

## Conditions studied

- Acute Respiratory Failure
- SARS CoV 2 Infection
- Anticoagulants

## Interventions

- **DRUG:** Enoxaparin Sodium
- **DRUG:** Bivalirudin

## Key facts

- **NCT ID:** NCT05334654
- **Lead sponsor:** University Magna Graecia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-20
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-07-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2022-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05334654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05334654, "Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05334654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*